<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56238">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374021</url>
  </required_header>
  <id_info>
    <org_study_id>2014P002747</org_study_id>
    <nct_id>NCT02374021</nct_id>
  </id_info>
  <brief_title>Treatments Against RA and Effect on FDG-PET/CT</brief_title>
  <acronym>TARGET</acronym>
  <official_title>Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized controlled clinical trial, investigators will compare the effects on
      [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from
      two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate
      responders (MTX-IRs). Two common RA treatments will be compared: triple therapy
      (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF)
      inhibitor (etanercept or adalimumab, plus background methotrexate).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting subjects will be screened for eligibility and randomized to a treatment arm.
      Subjects will be randomized to a treatment arm with either synthetic disease-modifying
      antirheumatic drugs (DMARDs) [triple therapy: sulfasalazine, methotrexate, and
      hydroxychloroquine] or biologic DMARDs [etanercept or adalimumab, plus background
      methotrexate].

      Once randomized, a baseline visit will be conducted with each subject. Baseline data
      collection includes questionnaires, disease activity score, and the first FDG-PET/CT
      imaging. After the baseline at week 0, subjects will visit with their rheumatologist at
      weeks 6, 12, 18, and 24 for safety labs and further collection of disease activity scores
      and questionnaires. The second FDG-PET/CT will be performed at week 24. Blood specimens will
      be collected at weeks 0, 6, 18, and 24 for bioassays. Subject participation will end after
      the week 24 visit.

      Patients and care providers will be unblinded. The FDG-PET/CT image readers will be blinded
      to treatment arm as well as timepoint of image acquisition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Vascular Inflammation as measured by FDG-PET/CT at 6 months</measure>
    <time_frame>0, 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Triple therapy (MTX+SSZ+HCQ)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate [MTX]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNF inhibitor (etanercept or adalimumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate). Biologic treatment will be assigned randomly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.</description>
    <arm_group_label>Triple therapy (MTX+SSZ+HCQ)</arm_group_label>
    <arm_group_label>TNF inhibitor (etanercept or adalimumab)</arm_group_label>
    <other_name>Rheumatrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>1 gm bid</description>
    <arm_group_label>Triple therapy (MTX+SSZ+HCQ)</arm_group_label>
    <other_name>Azulfidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>200 mg twice daily, not to exceed 6.5mg/kg</description>
    <arm_group_label>Triple therapy (MTX+SSZ+HCQ)</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>50 mg SC weekly</description>
    <arm_group_label>TNF inhibitor (etanercept or adalimumab)</arm_group_label>
    <other_name>enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>40 mg SQ every other week</description>
    <arm_group_label>TNF inhibitor (etanercept or adalimumab)</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfill American College of Rheumatology/European League Against Rheumatism 2010
             criteria for RA

          -  Men ≥ 45 years and women ≥ 50 years

          -  MTX monotherapy for ≥ 12 weeks at ≥ 15mg weekly

          -  No non-biologic DMARDs in preceding two months

          -  Disease Activity Score-28 &gt; 3.2

          -  Able to sign informed consent

        Exclusion Criteria:

          -  Prior use of biologic DMARD

          -  Current use of &gt;10mg per day of prednisone

          -  Use of a statin lipid lowering drug or PCSK9 inhibitor in the past 12 months

          -  Prior patient reported, physician diagnosed clinical cardiovascular (CV) event

          -  Diabetes mellitus (DM) or fasting blood glucose &gt;120mg/dL

          -  Systemic lupus erythematosus (SLE) or other autoimmune and chronic inflammatory
             diseases (i.e. inflammatory bowel disease, sarcoidosis)

          -  Cancer treated in the last 5 years (except basal and squamous cell) or any lymphoma
             or melanoma

          -  Known pregnancy, HIV, Hepatitis B Virus, Hepatitis C Virus, active (or untreated
             latent) tuberculosis

          -  Baseline: liver, renal or blood count abnormalities, Glucose-6-phosphate
             dehydrogenase (G6PD) deficiency

          -  Known sulfa allergy, macular disease or hypersensitivity to treatments; known
             demyelinating disease; uncompensated Congestive Heart Failure (CHF)

          -  Intra-articular injection with the 4 weeks prior to baseline FDG PET/CT

          -  2 or more high dose radiation scans in the past year (CT scan with contrast,
             angiogram, SPECT nuclear medicine scan, myocardial/cardiac perfusion scan)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Solomon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel H Solomon</last_name>
    <email>dsolomon@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joan Bathon</last_name>
    <email>jmb2311@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laticia Woodruff, RN</last_name>
      <phone>205-934-9843</phone>
      <email>lplove@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Curtis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigid Freyne, MD Inc.</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Rodriguez, MD</last_name>
      <phone>951-696-4600</phone>
      <email>Rguez.karla5@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Brigid Freyne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Fernandes</last_name>
      <email>ADFernandes@partners.org</email>
    </contact>
    <investigator>
      <last_name>Marcy Bolster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Wohlfahrt</last_name>
      <phone>617-525-8784</phone>
      <email>awohlfahrt@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Bourzikas, RN</last_name>
      <phone>314-747-8251</phone>
      <email>jbourzikas@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Parks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Bourzikas, RN</last_name>
      <phone>314-747-8251</phone>
      <email>jbourzikas@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Ritter</last_name>
      <email>michelle.ritter@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deborah Parks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Carlson, RN</last_name>
      <email>Cheryl.L.Carlson@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>William FC Rigby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cidney Schultz</last_name>
      <phone>718-918-6212</phone>
      <email>Cidney.Schultz@nbhn.net</email>
    </contact>
    <investigator>
      <last_name>Barbara Mendez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Whitfield</last_name>
      <email>DWhitfield@Winthrop.org</email>
    </contact>
    <investigator>
      <last_name>Steven Carsons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai- Icahn School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garnette Mason, MPH</last_name>
      <phone>212-241-4824</phone>
      <email>garnette.mason@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Yousaf Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Broderick</last_name>
      <phone>212-342-2713</phone>
      <email>rb3173@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Perry</last_name>
      <phone>216-444-4887</phone>
      <email>perrye2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Elaine Husni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Hope, RN</last_name>
      <phone>412-647-2638</phone>
      <email>hopelk@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Moreland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.targetra.org</url>
    <description>Study Website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>February 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Daniel H. Solomon, M.D.,MPH</investigator_full_name>
    <investigator_title>Chief, Section of Clinical Sciences</investigator_title>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
